Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165463 | 0.94 | NPC1 (0.45) | NPC1RAB9AMAPTMTNR1AMTNR1B | |
| SCHEMBL18148399 | 0.89 | KDM4E (0.44) | NPC1RAB9AMAPTMTNR1AMTNR1B | |
| SCHEMBL10721805 | 0.83 | ALDH1A1 (0.49) | CA1CA2ACHEKMT2AFAAH | |
| SCHEMBL2766220 | 0.83 | FAAH (0.47) | NPC1RAB9AMAPTCA1CA2 | |
| SCHEMBL29732553 | 0.83 | FAAH (0.47) | NPC1RAB9AMAPTCA1CA2 | |
| SCHEMBL346188 | 0.83 | SIRT2 (0.45) | RAB9AMAPTMTNR1AMTNR1BHDAC8 | |
| SCHEMBL346094 | 0.82 | CA1 (0.53) | MAPTMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL25554148 | 0.82 | MTNR1A (0.44) | MAPTMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL345462 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7919875 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC6 | NPC1 1322/4885RAB9A 2581/4885MAPT 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.